GO
Loading...

Takeover Bids

More

  • *AbbVie retracts claim that Shire investors support bid. LONDON, July 9- U.S. drugmaker AbbVie has been forced to retract comments by its chief executive about shareholder support for its bid for Shire after being caught out by British takeover rules.

  • LONDON, July 9- U.S. drugmaker AbbVie has been forced to retract comments by its chief executive about shareholder support for its bid for Shire after being caught out by British takeover rules. "AbbVie confirms that it has not received any written commitments of support and accordingly retracts the statements," it said on Wednesday.

  • Pershing Square offers slate for Allergan board Monday, 7 Jul 2014 | 3:49 PM ET

    July 7- William Ackman's Pershing Square Capital Management proposed on Monday a slate of six directors for the board of Allergan Inc as the hedge fund presses forward with its $53 billion takeover bid with Valeant Pharmaceuticals International Inc for the Botox maker.

  • MILAN/ PARIS, July 4- Late on May 23, Italian financier Andrea Bonomi phoned executives at his country's two largest banks seeking more than 200 million euros in loans to help him bid for French holiday resort company Club Mediterranee.

  • BRUSSELS/ FRANKFURT, July 2- European regulators have cleared Telefonica's bid to consolidate the German mobile market by buying smaller rival KPN's E-Plus for 8.6 billion euros, raising prospects of more deals to come across Europe's telecoms markets.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • June 30- Home healthcare service provider Gentiva Health Services Inc said its board had rejected an unsolicited offer from Kindred Healthcare Inc, saying the offer significantly undervalued the company.

  • CNBC's David Faber provides insight to AbbVie's $46 billion case to take over Shire.

  • *Move bolsters Shire in defence against AbbVie. *AbbVie to put its case to Shire shareholders- source. LONDON, June 25- Shire, which has spurned a $46 billion takeover offer from U.S. group AbbVie as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.

  • *Syngenta declines to comment on report of Monsanto talks. ZURICH, June 24- Syngenta's shares jumped on Tuesday after a media report that the Swiss crop chemical maker had been in talks about a $40 billion takeover by U.S. rival Monsanto Co to create the world's largest agrochemical company.

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • June 23- Allergan Inc on Monday advised investors not to sell their shares to Valeant Pharmaceuticals International which launched a hostile takeover offer for the California- based Botox maker last week, saying it was "grossly inadequate."

  • June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The offer price of about C $3.56 per Augusta common share represents a premium of about 11 percent to Augusta's Friday close on the Toronto Stock Exchange.

  • Augusta agrees to revised HudBay takeover offer Monday, 23 Jun 2014 | 7:10 AM ET

    June 23- Augusta Resource Corp said it agreed to be bought by HudBay Minerals Inc after the company raised its offer to buy Augusta shares it does not already own. The revised offer values Augusta at about C $555 million, HudBay said.

  • Cramer: AbbVie-Shire driven by inversion  Friday, 20 Jun 2014 | 9:07 AM ET

    British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.

  • Valeant goes hostile in bid for Allergan  Tuesday, 17 Jun 2014 | 8:37 AM ET

    Valeant says it will launch an exchange offer to Allergan shareholders, reports CNBC's Meg Tirrell.

  • Medtronic CEO: Focused on organic growth  Thursday, 5 Jun 2014 | 3:20 PM ET

    Omar Ishrak, Medtronic chairman & CEO, discusses the state of the health care industry and explains the extensive M&A activity happening in the sector.

  • Unusual options around Hillshire Brands  Tuesday, 3 Jun 2014 | 12:45 PM ET

    FMHR trader Pete Najarian takes a close look at unusual activity in options for Hillshire Brands, and the action in its stock as takeover talks continue.

  • Fight for Hillshire  Tuesday, 3 Jun 2014 | 9:02 AM ET

    Pilgrim's Pride is sweetening its takeover offer for Hillshire Brands. CNBC's Jim Cramer and David Faber discuss the "insane" bidding for Hillshire.